The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) applic ...

Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-38148 CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Utah 46-2609396 (State or other jurisdic ...

Exhibit 99.1 Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while ...

公司财务发布 - Co-Diagnostics, Inc.将于2024年5月9日发布2024年第一季度财务结果[1] - 公司将在当天下午4:30举行电话会议和网络直播，与分析师和机构投资者讨论财务结果，参与者可通过公司网站进行观看[1] 公司背景介绍 - Co-Diagnostics, Inc.是一家总部位于犹他州的分子诊断公司，开发、制造和销售最先进的诊断技术，主要用于检测和/或分析核酸分子（DNA或RNA）[3]

SALT LAKE CITY, April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan. The theme for the 2024 conference is "Shapin ...

公司新设施剪彩仪式 - Co-Diagnostics, Inc.宣布在南盐湖市举行了新制造设施的剪彩仪式[1] - 新设施将用于生产Co-Dx Pro™仪器和测试杯，以及公司专利的Co-Primers™化学[1] - CEO Dwight Egan表示，新设施标志着Co-Diagnostics在本地社区和国际舞台上的重要一步[3] - Mayor Wood表示对Co-Diagnostics在南盐湖市建立制造园区的计划感到高兴[3] - BioUtah的Kelyvn Cullimore认为Co-Diagnostics的成功体现了犹他州的创业精神[4] - Co-Diagnostics是一家开发、制造和销售最先进诊断技术的分子诊断公司[5]

任命新高管 - Co-Diagnostics, Inc.宣布任命Richard Abbott为总裁，David Nielsen为首席运营官，Christopher Thurston为首席技术官，Seth Egan为首席商业化官[1] - Richard Abbott在Advanced Conceptions, Inc.担任总裁，具有超过25年的体外诊断公司高级领导职位经验[1] - David Nielsen曾在Idaho Molecular担任首席运营官，拥有超过25年的研发技术和领导经验[2] - Christopher Thurston在Ernst and Young、BioFire Defense和BioMerieux等公司担任高级开发人员和软件平台架构师[3] - Seth Egan自公司成立以来一直担任销售、营销和产品商业化工作，对公司的销售团队起着重要作用[4]

公司新设施开幕 - 公司CEO Dwight Egan在伦敦的第五届MarketsandMarkets会议上宣布了新的盐湖城制造设施的开幕[1] 印度合资制造 - 公司与CoSara Diagnostics合资在印度进行制造，将生产Co-Dx™ PCR Pro™仪器和Co-Dx PCR测试杯[2] 商业化新平台计划 - 公司计划在商业化新平台前进行内部生产试剂、设备和消耗品，以及推出其他产品，如结核病检测[3]

SALT LAKE CITY, Utah, March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England. Mr. Egan will be delivering the keyno ...